ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Safety and Efficacy of Direct-Acting Oral Anticoagulants versus Warfarin in Kidney Transplant Recipients

A. L. Bixby1, S. A. Shaikh2, A. S. Naik3, L. Cotiguala3, K. McMurry3, M. D. Samaniego-Picota4, V. D. Marshall5, J. M. Park3

1University Hospitals Cleveland Medical Center, Cleveland, OH, 2Keck Medical Center of USC, University of Southern California, Los Angeles, CA, 3Michigan Medicine, Ann Arbor, MI, 4Henry Ford Transplant Institute, Detroit, MI, 5University of Michigan College of Pharmacy, Ann Arbor, MI

Meeting: 2020 American Transplant Congress

Abstract number: C-034

Keywords: Anticoagulation, Kidney transplantation

Session Information

Session Name: Poster Session C: Kidney: Cardiovascular and Metabolic Complications

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Safety and efficacy of direct-acting oral anticoagulants (DOACs) have not been well studied in solid organ transplant. The purpose of our study was to compare the safety and efficacy of DOACs to warfarin in kidney transplant recipients.

*Methods: In this single-center retrospective study, we evaluated 197 adult kidney transplant recipients who initiated DOAC or warfarin between January 2011 to June 2018. The primary outcome was major bleeding defined as Hgb decrease ≥ 2 g/dl, blood transfusion ≥ 2 units, or symptomatic bleeding in a critical area or organ.

*Results: Patients were initiated on oral anticoagulation at a median of 6.5 years post-transplant and followed for a median of 12.3 (IQR 5.2-27.5) months. Baseline characteristics were well matched, except for calendar year of anticoagulation initiation, Hgb, and concomitant antiplatelet use at time of anticoagulation initiation (Table 1). Rates of major bleeding were 11.4% per year with warfarin vs. 7.2% per year with DOACs (Figure 1, Mantel-Cox p=0.15). No difference was found in composite bleeding, clinically relevant nonmajor bleeding, or thromboembolic events (Table 2). There was a lower incidence of major bleeding with apixaban compared to all other anticoagulants (6.7% vs. 19.0%, P=0.027). After controlling for potential confounders, DOAC use was not associated with an increased risk of major bleeding (HR 0.93, 95% CI 0.27-1.95).

*Conclusions: These findings indicate that DOACs are safe and effective alternatives to warfarin for anticoagulation in kidney transplant recipients.

 border=

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Bixby AL, Shaikh SA, Naik AS, Cotiguala L, McMurry K, Samaniego-Picota MD, Marshall VD, Park JM. Safety and Efficacy of Direct-Acting Oral Anticoagulants versus Warfarin in Kidney Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/safety-and-efficacy-of-direct-acting-oral-anticoagulants-versus-warfarin-in-kidney-transplant-recipients/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences